The Curative Potential of CAR-T Cell Therapy in Mantle Cell Lymphoma

Video

Though it is still being tested in clinical trials, CAR-T cell therapy can offer hope for patients with mantle cell lymphoma whose disease relapsed.

Chimeric antigen receptor (CAR)-T cell therapy is generating excitement across blood cancers, and may eventually be an appealing option for patients with mantle cell lymphoma (MCL), said Andre Goy, M.D., M.S., chief, Division of Lymphoma, chairman and director of the John Theurer Cancer Center.

The ongoing ZUMA-2 trial is exploring the possibility of CAR-T cell therapy in patients with relapsed or refractory MCL. While official results are not out yet, Goy mentioned that the researchers are seeing a high response rate and promising results in this patient population.

Goy said that CAR-T cell therapy is particularly appealing in patients with MCL who eventually develop a resistance to chemotherapy. CAR-T cells can offer a new line of therapy in a setting that traditionally had very few options.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey. If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key. “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained. READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content
Image of lymphoma cells.

Calquence Regimen Improves Outcomes in Frontline Mantle Cell Lymphoma

May 2nd 2024
Article

Adding Calquence to standard-of-care chemoimmunotherapy improved progression-free survival in patients with previously untreated mantle cell lymphoma.

Read More

Dr. Jennifer Plichta in an interview with CURE

Genetic Testing for Breast Cancer May Benefit Family Members

March 12th 2024
Article

An expert explained that patients with breast cancer who undergo genetic testing may help their family members, regardless of whether patients have children.

Read More

blood cancer cells floating. A novel CD NK therapy could benefit patients with lymphoma, CLL, SLL, mantle cell lymphoma, among others.

Cord Blood-Derived Treatment Shows Promise in Blood Cancer

January 25th 2024
Article

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

Read More

Target on a cancer cell

‘Remarkable’ Results from Tecartus in Patients With R/R MCL

January 4th 2024
Article

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

Read More

3 Topics Patients Should Discuss With Their Oncology Teams

3 Topics Patients Should Discuss With Their Oncology Teams

January 4th 2024
Article

An expert discusses three crucial conversations about cancer care that patients should have with their health care providers.

Read More

target on cancer cell

Tecartus Induces Responses in Real-World Population of High-Risk R/R MCL

December 10th 2023
Article

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Read More